SLC5A2 and diabetes mellitus: It was shown that empagliflozin, which is a sodium-glucose cotransporter 2 (SGLT2) inhibitor useful for treating diabetes mellitus (DM) patients, can regulate sestrin2, the AMPK-mTOR pathway, and ROS homeostasis to improve obesity-related cardiac dysfunction in mice [128].